SCHEMBL6366603

SCHEMBL6366603

C/C(=C\c1ccc(I)cc1)CO

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CAPN1 P07384 1/20 0.42
CAPN2 P17655 1/20 0.42
APP P05067 1/20 0.36
TRPA1 O75762 4/20 0.33
ESR1 P03372 2/20 0.33
ESR2 Q92731 2/20 0.33
ALDH1A1 P00352 2/20 0.32
KDM4E B2RXH2 1/20 0.32
USP2 O75604 1/20 0.31
ALOX15 P16050 1/20 0.31
TSHR P16473 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP2D6 P10635 1/20 0.31
NQO2 P16083 1/20 0.31
PTGS1 P23219 1/20 0.31
PTGS2 P35354 1/20 0.31
GLA P06280 1/20 0.31
POLB P06746 1/20 0.31
TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6366611 1.00 CAPN1 (0.42) CAPN1CAPN2APPTRPA1ESR1
SCHEMBL5226684 0.81 CAPN1 (0.41) CAPN1CAPN2APPTRPA1ESR1
SCHEMBL5226682 0.81 CAPN1 (0.41) CAPN1CAPN2APPTRPA1ESR1
SCHEMBL1758165 0.80 CYP2A6 (0.41) KDM4ESMN1; SMN2PTGS1PTGS2POLB
SCHEMBL1758330 0.80 CYP2A6 (0.41) KDM4ESMN1; SMN2PTGS1PTGS2POLB
SCHEMBL3600589 0.78 KMT2A (0.44) TRPA1ALDH1A1KDM4EUSP2SMN1; SMN2
SCHEMBL4631940 0.78 APP (0.40) APPTRPA1ESR1ESR2ALDH1A1
SCHEMBL3602795 0.78 TRPA1 (0.55) TRPA1CYP1A2PTGS2ABCB11SIGMAR1
SCHEMBL3602792 0.78 TRPA1 (0.55) TRPA1CYP1A2PTGS2ABCB11SIGMAR1
SCHEMBL4632154 0.78 TRPA1 (0.50) TRPA1ALDH1A1CYP1A2PTGS1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3286172-B1 LSD1 INHIBITORS AND USES THEREOF CONSTELLATION PHARMACEUTICALS INC (US) 2019-06-12 EP disclosed
EP-3286172-B1 LSD1 INHIBITORS AND USES THEREOF CONSTELLATION PHARMACEUTICALS INC (US) 2019-06-12 EP disclosed
US-20180290976-A1 LSD1 INHIBITORS AND USES THEREOF CONSTELLATION PHARMACEUTICALS, INC. 2018-10-11 US disclosed
EP-3286172-A1 LSD1 INHIBITORS AND USES THEREOF Constellation Pharmaceuticals, Inc. (US) 2018-02-28 EP disclosed
WO-2016172496-A1 LSD1 INHIBITORS AND USES THEREOF CONSTELLATION PHARMACEUTICALS, INC. (US) 2016-10-27 WO disclosed
WO-2016172496-A1 LSD1 INHIBITORS AND USES THEREOF CONSTELLATION PHARMACEUTICALS, INC. (US) 2016-10-27 WO disclosed
US-20050245529-A1 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180290976-A1 LSD1 INHIBITORS AND USES THEREOF KDM1B, KDM1A, KDM2A CAPN1 1166/4885CAPN2 1546/4885APP 2848/4885
US-20050245529-A1 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds MCHR1, GPR119, MCHR2 CAPN1 3507/4885CAPN2 3983/4885APP 3959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.